Bill Anderson (businessman)

Last updated

Bill Anderson
Bill Anderson (born 1966) at World Economic Forum Davos 2024.png
At World Economic Forum 2024
Born (1966-08-23) August 23, 1966 (age 57)
Ohio, Texas, U.S.
Alma mater University of Texas at Austin
Massachusetts Institute of Technology
Occupation(s) Business executive
Chemical engineer
Employer(s) Bayer
Roche
Genentech
Children3

William Anderson (born August 23, 1966) is an American business executive who has been the chief executive officer (CEO) of Bayer AG since June 2023. [1] [2]

Contents

Prior to his current role, Anderson was CEO of Genentech from 2017 to 2018, and later CEO of the Roche's Pharmaceuticals Division from 2019 to 2022. [3] [4]

Early life and education

Anderson was born on August 23, 1966, in Ohio, Texas. [5] He holds a bachelor's degree in chemical engineering from the University of Texas at Austin and a master's degree in management and chemical engineering from the Massachusetts Institute of Technology (MIT). [6] [7]

Anderson is married and has three children. [7]

Career

Anderson started his career in 1989 as a process engineer for research and development at Ethyl Corporation in the Netherlands and Belgium. [6] From 1995 to 1997, he worked as a marketing manager for Raychem. [6]

From 1997 to 2006, Anderson worked at Biogen in multiple countries, including, Ireland, the U.S., and the U.K., holding positions such as vice president and general manager of the neurology business at Biogen. [6] [8]

In 2006, Anderson joined Genentech, where he eventually became the senior vice president of the immunology, ophthalmology and bio-oncology divisions. [9]

In 2013, Anderson moved to Switzerland to be head of global product strategy and chief marketing officer of the pharmaceuticals division at the Roche Holding AG. [9]

In July 2016, Anderson returned to the U.S. to lead North American Operations at Roche's subsidiary, Genentech. [6] From 2017 to 2018, he was the CEO of Genentech. [6] While at Genentech, he developed its immunology and ophthalmology divisions, managed the sales of Rituxan, Raptiva, and Xolair, and directed Roche's late-stage portfolio committee for nearly four years, where he was responsible for determining late-stage clinical trial advancements. [6]

Anderson visit Chongqing, China, 2024 Bill Anderson 2024.jpg
Anderson visit Chongqing, China, 2024

From 2019 to 2022, Anderson was CEO of Roche's pharmaceuticals division. [9] [10] During Anderson's tenure at Roche, he facilitated the company's transition from a focus on oncology. He headed the development and launch of new drugs to compensate for the decrease in revenues from oncology drugs whose patents had expired. [11]

On June 1, 2023, Anderson assumed the role of CEO of Bayer AG, succeeding Werner Baumann. [12] The selection process had begun in mid-2022 and by April 2023, he became a member of the Board of Management of Bayer AG. [11] He is the second foreigner to lead Bayer after Marijn Dekkers, and he is the second CEO in Bayer's history to be hired from outside the company after Dekkers. [7]

Related Research Articles

Genentech, Inc. is an American biotechnology corporation headquartered in South San Francisco, California. It became an independent subsidiary of Roche in 2009. Genentech Research and Early Development operates as an independent center within Roche. Historically, the company is regarded as the world's first biotechnology company.

<span class="mw-page-title-main">Biogen</span> Pharmaceutical company

Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, United States specializing in the discovery, development, and delivery of therapies for the treatment of neurological diseases to patients worldwide. Biogen operates in Argentina, Brazil, Canada, China, France, Germany, Hungary, India, Italy, Japan, Mexico, Netherlands, Poland, Sweden, and Switzerland.

<span class="mw-page-title-main">Roche</span> Swiss multinational healthcare company

F. Hoffmann-La Roche AG, commonly known as Roche, is a Swiss multinational holding healthcare company that operates worldwide under two divisions: Pharmaceuticals and Diagnostics. Its holding company, Roche Holding AG, has shares listed on the SIX Swiss Exchange. The company headquarters are located in Basel. Roche is the fifth-largest pharmaceutical company in the world by revenue and the leading provider of cancer treatments globally. In 2023, the company’s seat in Forbes Global 2000 was 76.

<span class="mw-page-title-main">Chiron Corporation</span> American biotechnology firm (1981-2006)

Chiron Corporation was an American multinational biotechnology firm founded in 1981, based in Emeryville, California, that was acquired by Novartis on April 20, 2006. It had offices and facilities in eighteen countries on five continents. Chiron's business and research was in three main areas: biopharmaceuticals, vaccines, and blood testing. Chiron's vaccines and blood testing units were combined to form Novartis Vaccines and Diagnostics, while Chiron BioPharmaceuticals was integrated into Novartis Pharmaceuticals. In 2014, Novartis completed the sale of its blood transfusion diagnostics unit to Grifols and announced agreements for the sale of its vaccines unit to GlaxoSmithKline.

Exelixis, Inc. is a genomics-based drug discovery company located in Alameda, California, and the producer of Cometriq, a treatment approved by the U.S. Food and Drug Administration (FDA) for medullary thyroid cancer with clinical activity in several other types of metastatic cancer.

Arthur D. Levinson is an American businessman and is the chairman of Apple Inc. (2011–present) and chief executive officer (CEO) of Calico. He is the former CEO (1995–2009) and chairman (1999–2014) of Genentech.

OSI Pharmaceuticals, Inc. was an American pharmaceutical company formerly based in Long Island, New York with facilities in Colorado, New Jersey and the United Kingdom. On Sunday, May 16, 2010 OSI agreed to be acquired by Japan-based, TSE-listed Astellas Pharma for $4.0 billion. The deal was closed on June 9, 2010. The company closed its last facilities in Long Island in May 2013. OSI had specialized in the discovery and development of molecular targeted therapies. Though oncology was the top priority for OSI, research and development targeting type 2 diabetes and obesity had been conducted through their U.K. subsidiary Prosidion Limited. OSI had also made a foray into the ophthalmology market through a marketing agreement with Pfizer over Macugen (Pegaptanib) for Age-related macular degeneration; however, acquisition of the firm Eyetech, meant to provide control over this product and diversify the company, was unsuccessful, ending in divestiture.

<span class="mw-page-title-main">Severin Schwan</span> Businessman (born 1967)

Severin Anton Schwan is an Austrian business executive. He is the current chairman of the board and former CEO (2008–2023) of the Roche Group.

<span class="mw-page-title-main">Galena Biopharma</span> American pharmaceutical company

Galena Biopharma was a publicly traded pharmaceutical company based in San Ramon, California. The company was founded in Worcester, Massachusetts. In 2011, it moved to Oregon, and in 2015 moved to San Ramon, California. Mark Schwartz was the company's president and chief executive officer. As of December 29, 2017, the company was acquired by Sellas Life Sciences Group Ltd. through a reverse merger transaction. Galena Biopharma was renamed to Sellas Life Sciences Group, Inc.

<span class="mw-page-title-main">Pascal Soriot</span> French businessman

Sir Pascal Claude Roland Soriot is a French-born Australian businessman and chief executive officer (CEO) of the British-Swedish multinational pharmaceutical and biotechnology company AstraZeneca.

Alnylam Pharmaceuticals, Inc. is an American biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. In 2016, Forbes included the company on its "100 Most Innovative Growth Companies" list.

Calico Life Sciences LLC is a subsidiary of Alphabet Inc. and with a focus on biotechnology their goal is to increase the understanding of the biology that controls human aging, attempting to devise interventions that may enable people to lead longer and healthier lives.

<span class="mw-page-title-main">Pharmaceutical industry in Switzerland</span> Overview of the pharmaceutical industry in Switzerland

The pharmaceutical industry in Switzerland directly and indirectly employs about 135,000 people. It contributes 5.7% of the gross domestic product of Switzerland and 30% of the country's exports. In 2017 about 30% of Swiss exports were chemical products. In the same year Switzerland was the second largest exporter of packaged medicine in the world, with about 11% of the global total, worth $36.5 billion.

BioMotiv is an accelerator company associated with The Harrington Project, an initiative centered at University Hospitals of Cleveland. Therapeutic opportunities were identified through relationships with The Harrington Discovery Institute, university and research institutions, disease foundations, and industry sources. Once opportunities are identified, BioMotiv oversees the development, funding, active management, and partnering of the therapeutic products.

<span class="mw-page-title-main">Robert A. Bradway</span> American businessman

Robert A. Bradway is an American businessman. He is the chairman and chief executive officer of Amgen.

Rinat Neuroscience Corporation was a privately held biotechnology company that discovered and developed antibody-based drugs, including:

<span class="mw-page-title-main">Werner Baumann</span> German businessman and CEO of Bayer

Werner Baumann is a German businessman who was the chief executive officer (CEO) of Bayer from 2016 to May 2023.

Marijn Emmanuel Dekkers is a Dutch-American former pharmaceutical businessman. He was CEO of Bayer AG from 2010 to 2016. He was CEO of Thermo Fisher Scientific Inc. from 2002 to 2009. He was Chairman of Unilever from 2016 to 2019. He is also Founder and Chairman of Novalis LifeSciences LLC, an investment and advisory firm for the Life Science industry.

<span class="mw-page-title-main">William Rastetter</span> American scientist, entrepreneur and venture capitalist

William H.Rastetter, a scientist, entrepreneur and venture capitalist, is the chair of Neurocrine Biosciences, of Fate Therapeutics, and of Daré Bioscience, Inc. in San Diego, California. He is a founding board member and investor in GRAIL, Inc. in Menlo Park, California, and served for a period as the company's interim CEO (2017) and chair (2017-2018). Rastetter is also a director of Regulus Therapeutics and Entos, Inc.. He was a partner in the venture firm Venrock (2006-2013), and a trustee at Caltech (2015-2018). He has served as a director (1998-2016) and as chair of Illumina (2005-2016). He advised SVB Leerink (2014-2019) and currently advises Illumina Ventures.

<span class="mw-page-title-main">Frederick Frank (businessman)</span>

Frederick Frank CFA was an investment banker, with more than 50 years of experience on Wall Street. He is considered the first investment banker to have specialized in the areas of biotechnology, pharmaceuticals, and health care services.

References

  1. ↑ "Wechsel an der Spitze – Bill Anderson übernimmt das Ruder". Handelsblatt . June 1, 2023.
  2. ↑ Jansen, Jonas (February 8, 2023). "Roche-Manager Bill Anderson wird neuer Bayer-Chef". Frankfurter Allgemeine Zeitung .
  3. ↑ Roland, Denise (December 10, 2018). "Roche Taps Genentech Chief to Lead Pharmaceuticals Division". Wall Street Journal .
  4. ↑ "Bayer-Chef Baumann tritt ab, Bill Anderson übernimmt". Manager Magazin . February 8, 2023.
  5. ↑ Boston, William (April 5, 2023). "Bayer's New American CEO to Study Wounded Pharma Giant Before Acting". Wall Street Journal .
  6. 1 2 3 4 5 6 7 Leuty, Ron (June 8, 2017). "Can new Genentech CEO Bill Anderson keep and build on the biotech's 'casual intensity'?". San Francisco Business Journal.
  7. 1 2 3 Höning, Von Antje (February 8, 2023). "Ein Amerikaner wird Bayer-Chef". Rheinische Post .
  8. ↑ Käding, Von Thomas (August 2, 2023). "Der Kalifornier Bill Anderson soll Bayer führen". Kölner Stadt-Anzeiger .
  9. 1 2 3 Leuty, Ron (December 9, 2018). "Roche vet named Gilead CEO — and Genentech boss moves to Switzerland — in shuffle of top Bay Area biotech execs". San Francisco Business Times.
  10. ↑ Leuty, Ron (December 12, 2022). "Former Genentech CEO to leave parent company Roche". San Francisco Business Times.
  11. 1 2 "Bayer picks outsider Anderson as CEO after investor pressure". Reuters . February 9, 2023.
  12. ↑ Boston, William; Thomas, Patrick (February 8, 2023). "Bayer Hires Former Roche Executive to Succeed CEO Werner Baumann". Wall Street Journal .
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.